



uCor V1.0.0

FCC ID: 2ABHFUCOR100

Jan. 1<sup>st</sup>, 2014

**Subject: Kyma uCor 100 Confidentiality Request**

***To whom it may concern***

Kyma Medical Technologies requests for Long Term Confidentiality and Short Term Confidentiality with respect to the following list of exhibits related with its application for certification, and that this information be withheld from public disclosure pursuant to 47 CFR section 0.457(d) & 0.459 of the commission's rules, since it considered as Kyma Intellectual Property, Privilege and Trade Secret.

*Long Term Confidentiality Exhibit Request:*

- A. CONF APPENDIX uCOR V1.0.0 Schem.pdf
- B. CONF APPENDIX uCOR V1.0.0 Partlst.pdf
- C. CONF APPENDIX uCOR V1.0.0 BlkDia.pdf
- D. CONF APPENDIX uCOR V1.0.0 OpDes.pdf and all subsequent revisions
- E. CONF APPENDIX uCOR V1.0.0 FCC and Kyma Attorney Correspondence.pdf
- F. CONF APPENDIX UCOR V1.0.0 7.18.2012 ElectroMagnetic Emission Testing Report.pdf

Kyma's uCor V1.0.0 is not a consumer product and therefore its records above are not routinely available for public inspection.

*Short Term Confidentiality Exhibit Request:*

- G. CONF APPENDIX uCOR V1.0.0 IntPho.pdf and all subsequent revisions

Kyma's uCor V1.0.0's first marking launch is planned for June 2015 after the product receives FDA approval, therefore the product cannot be disassembled or inspected by any commercial or private entity before that time.

Kyma also declares that any uCor V1.0.0 commercialization during the Short Term period will follow the proper NDA requirement pursuant to the requirement of confidentiality by the purchaser.

The records above for which Confidentiality is required consist of confidential Intellectual Proprietary that was developed, researched and funded by Kyma over the last 5 years; therefore, publication of the said information will damage Kyma considerably by exposing it to competition.

Thank you for cooperation and understanding of this matter.

Sincerely,

Moshe Mosesko

COO of Kyma Medical Technologies Ltd.